Fig. 5.

High density lipoprotein-mediated proliferation of human adipose-derived stem cells is significantly decreased when treated with signal pathway inhibitors (LY294002 or/and PD98059). a MTT and b bromodeoxyuridine (BrdU) assay: human mice adipose-derived stem cells (ADSCs) were pretreated with LY249002 or/and PD98059 for 2 hours prior to 24-hour incubation with high density lipoprotein (HDL). Data show that the proliferation of human ADSCs was obviously inhibited with LY249002 and PD98059 treatment. c Western blot change in expression of various signal pathway molecules and cell cycle regulatory proteins in human ADSCs that were pretreated with LY249002 or/and PD98059 for 2 hours prior to 1-hour incubation with HDL. d p-Akt, e p-ERK, f cyclin D₁, g cyclin E, h p21, i p27. Results are the mean ± standard error of three experiments for each condition determined by densitometry relative to corresponding total protein/beta-actin. *P <0.05, **P <0.01, ***P <0.001